In consultation with Health Canada, four companies (Cobalt Pharmaceuticals, Laboratoire Riva, Mylan Pharmaceuticals and Sanis Health) are voluntarily recalling various lots of five prescription drugs (amlodipine, ciprofloxacin, lamotrigine, norfloxacin and telmisartan) from the Canadian market (see chart below). The voluntary recall is a precautionary measure due to quality concerns at the manufacturing facility of the active ingredients used in the products. The issues are primarily around processes that affect quality control and oversight.
To read the full article, click here.
ONE in 20 children whose mothers used a drug to treat epilepsy during pregnancy suffers from an autistic disorder, research suggests.
A study involving 655,615 children born between 1996 and 2006 found that 4.42 per cent of those whose mothers used the drug valproate while pregnant were diagnosed with an autism- spectrum disorder, which can range from mild to more severe forms. The research also found that 2.5 per cent were found to have childhood autism.
Please click hereto read the full story and learn more about the research conducted.
Please find the attached stakeholder information package for the Canada/U.S. Medical Reciprocity Agreement for Commercial Drivers (W Code). It contains a stakeholder letter, a sample of the notificaion letter sent to drives, and a question and answer sheet.
On March 7th, 2013 Global News Toronto launched "Inside Epilepsy," a series highlighting what it means to live with a seizure disorder. Thanks to the courage of Global News Reporter, Mark McAllister, and other individuals for sharing their personal experiences they are shining the light and stamping out stigma for those living with epilepsy.
Below are the links for the video series. Please take the time to check these out and learn how you can help educate others on epilepsy to show these individuals they are not alone.
March 5th, 2013
Pfizer has reported that they are experiencing a shortage of Neurontin tablets (600 mg) which is expected to be resolved by March 15, 2013.
Epilepsy Ontario contacted Pfizer's customer service department and learned that all other strengths of Neurontin are available: 100 mg, 300 mg and 400 mg capsules, and 800 mg tablets.
This temporary shortage appears to be restricted to the 600 mg Neurontin tablets only. There is no indication that any other brands or dosages of gabapentin are affected. If you take Neurontin 600 mg tablets, contact your pharmacist for more information and to ask whether they have the medication in stock.
For additional information visit the
Canadian Drug Shortages Database.
Pfizer Canada Inc., Customer Service Department 1-888-275-9938
(Adapted from Epilepsy Ontario - Voices of